- Home
- GLOB vs RYTM Comparison
GLOB vs RYTM Comparison
Compare GLOB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLOB
- RYTM
- Stock Information
- Founded
- GLOB 2003
- RYTM 2008
- Country
- GLOB Luxembourg
- RYTM United States
- Employees
- GLOB N/A
- RYTM N/A
- Industry
- GLOB EDP Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- GLOB Technology
- RYTM Health Care
- Exchange
- GLOB Nasdaq
- RYTM Nasdaq
- Market Cap
- GLOB 4.7B
- RYTM 4.3B
- IPO Year
- GLOB 2014
- RYTM 2017
- Fundamental
- Price
- GLOB $92.76
- RYTM $89.00
- Analyst Decision
- GLOB Buy
- RYTM Strong Buy
- Analyst Count
- GLOB 16
- RYTM 13
- Target Price
- GLOB $174.94
- RYTM $80.08
- AVG Volume (30 Days)
- GLOB 1.0M
- RYTM 806.9K
- Earning Date
- GLOB 08-14-2025
- RYTM 08-05-2025
- Dividend Yield
- GLOB N/A
- RYTM N/A
- EPS Growth
- GLOB N/A
- RYTM N/A
- EPS
- GLOB 3.38
- RYTM N/A
- Revenue
- GLOB $2,455,696,000.00
- RYTM $136,863,000.00
- Revenue This Year
- GLOB $4.36
- RYTM $37.56
- Revenue Next Year
- GLOB $6.03
- RYTM $74.99
- P/E Ratio
- GLOB $27.51
- RYTM N/A
- Revenue Growth
- GLOB 11.90
- RYTM 48.88
- 52 Week Low
- GLOB $86.02
- RYTM $40.61
- 52 Week High
- GLOB $238.32
- RYTM $88.99
- Technical
- Relative Strength Index (RSI)
- GLOB 44.38
- RYTM 82.22
- Support Level
- GLOB $89.74
- RYTM $64.65
- Resistance Level
- GLOB $94.59
- RYTM $67.75
- Average True Range (ATR)
- GLOB 3.12
- RYTM 2.88
- MACD
- GLOB 0.98
- RYTM 1.71
- Stochastic Oscillator
- GLOB 72.94
- RYTM 99.82
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.